Gene expression and risk of leukemic transformation in myelodysplasia.
暂无分享,去创建一个
Satoru Miyano | Yuichi Shiraishi | Kenichi Chiba | Luca Malcovati | Eva Hellström-Lindberg | Mohsen Karimi | Mario Cazzola | Seishi Ogawa | Hiromichi Suzuki | Hideki Makishima | Kenichi Yoshida | M. Cazzola | S. Miyano | Y. Shiraishi | K. Chiba | Hiromichi Suzuki | S. Ogawa | Y. Shiozawa | Yusuke Sato | T. Yoshizato | A. Sato-Otsubo | Kenichi Yoshida | E. Hellström-Lindberg | H. Makishima | J. Boultwood | L. Malcovati | A. Pellagatti | A. Gallì | M. Karimi | Andrea Pellagatti | Jacqueline Boultwood | Yusuke Sato | Yusuke Shiozawa | Anna Gallì | Tetsuichi Yoshizato | Aiko Sato-Otsubo | Hiromichi Suzuki
[1] W. Evans,et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.
[2] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[3] P. Campbell,et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.
[4] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[5] Claude Preudhomme,et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.
[6] H. Kantarjian,et al. A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.
[7] J. Melo,et al. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. , 2007, Blood.
[8] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[9] M. Lichtman. Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia. , 2013, The oncologist.
[10] H. Preisler,et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. , 1995, Blood.
[11] A. Schambach,et al. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes , 2012, Annals of Hematology.
[12] Nathan C Boles,et al. Less is more: unveiling the functional core of hematopoietic stem cells through knockout mice. , 2012, Cell stem cell.
[13] M. Cazzola,et al. The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.
[14] H. Preisler,et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis , 1995, American journal of hematology.
[15] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[17] Angelo J. Canty,et al. Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.
[18] M. Caligiuri,et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Stephen L. Abrams,et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy , 2008, Leukemia.
[20] T. Naoe,et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. , 2004, Blood.
[21] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[22] M. Odero,et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. , 2010, Blood.
[23] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[24] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[25] Robert Tibshirani,et al. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. , 2009, Blood.
[26] M. Cazzola,et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. , 2009, Blood.
[27] Torsten Haferlach,et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. , 2009, Blood.
[28] J. Issa,et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.
[29] T. Giese,et al. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy , 2016, International journal of cancer.
[30] Rafael A. Irizarry,et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .
[31] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[32] S. Miyano,et al. Dynamics of clonal evolution in myelodysplastic syndromes , 2016, Nature Genetics.
[33] Randy J. Read,et al. Transcriptional diversity during lineage commitment of human blood progenitors , 2014, Science.
[34] Benjamin L Ebert,et al. Molecular pathophysiology of myelodysplastic syndromes. , 2013, Annual review of pathology.
[35] Ali H. Brivanlou,et al. Signaling Pathways in Cancer and Embryonic Stem Cells , 2007, Stem Cell Reviews.
[36] J. Kutok,et al. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. , 2011, Blood.
[37] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[38] E Mardis,et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes , 2013, Leukemia.
[39] M. Cazzola,et al. Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes , 2012 .
[40] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[41] M. Cazzola,et al. Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells. , 2009 .
[42] Brian P. Brunk,et al. Comparative analysis of RNA-Seq alignment algorithms and the RNA-Seq unified mapper (RUM) , 2011, Bioinform..
[43] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[44] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Bob Löwenberg,et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. , 2003, Blood.
[46] E. Vellenga,et al. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? , 2006, Human molecular genetics.
[47] H. Aburatani,et al. Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.
[48] R. Eils,et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. , 2014, Cell stem cell.
[49] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[50] Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .
[51] M. Caligiuri,et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.
[52] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[53] R. Deberardinis,et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis , 2017, Nature.
[54] Di Wu,et al. ROAST: rotation gene set tests for complex microarray experiments , 2010, Bioinform..
[55] Zoltan Szallasi,et al. Jetset: selecting the optimal microarray probe set to represent a gene , 2011, BMC Bioinformatics.